Society for Clinical Research Sites Launches the Site Advocacy Group Initiative Program Will Drive Research Collaboration, Enhance Site Sustainability
ELLICOTT CITY, Md., April 23, 2014 /PRNewswire/ -- The Society for Clinical Research Sites (SCRS) is proud to announce the launch of its newest initiative, the Site Advocacy Group (SAG). SCRS is honored to have TransCelerate BioPharma Inc. ("TransCelerate") as its SAG partner.
The SAG is a landmark industry initiative that enables clinical investigators and site professionals to interact directly with senior industry leaders in the exchange of perspectives and experiences on innovative ideas, processes, tools and technologies. The knowledge gained will help to promote site sustainability, enhance clinical research effectiveness and more closely align the work of the sites and industry across the research ecosystem.
"By bringing together the global site community, SCRS has actively advocated for the sustainability of all sites. The formation of the SAG is the most recent example," stated Christine Pierre, President of the Society for Clinical Research Sites. "It marks a true coalescence of major industry stakeholders working together towards mutually beneficial and respectful outcomes with the sites. This commitment by TransCelerate, representing 19 major sponsors, demonstrates a true commitment to the site community through SCRS' SAG."
In this groundbreaking program, SCRS members representing a broad spectrum of site professionals and clinical research sites will partner with TransCelerate workstream members to exchange practical feedback on various topics. In return, industry leaders will share with the sites their key priorities and initiatives to elevate the ecosystem.
"TransCelerate is thrilled to partner with SCRS, a global organization created by the investigator community to advocate for the investigator community," said Dalvir Gill, PhD, Chief Executive Officer of TransCelerate. "This SAG program will provide TransCelerate workstreams direct access to the voice of investigative sites around the world, gather timely input and feedback on projects and further optimize the impact we can make on clinical trials efficiency."
Moving forward, outcomes from the SAG initiative will help to inform collaborative initiatives within the industry aimed at enhancing safety, efficiency, and innovation. Results from the SAG initiative will also be poised to enhance operational and business performance for the sites.
"This program harnesses the power of partnership and collaboration," added SCRS' Pierre. "Integrating the perspectives of clinical sites and investigators with those of industry elevates the work of all. We are grateful for the partnership and leadership of TransCelerate in this landmark collaboration."
SCRS is a trade organization representing global clinical research sites representing 1,400 sites in 22 countries since its inception in 2012. SCRS' mission is to unify and amplify the voice of the global clinical research site community for site sustainability. SCRS has become an active partner in industry-wide dialogues focused on improving the clinical research enterprise among the many industry initiatives. Sites, as well as companies that sponsor or support the work conducted at the clinical research sites, will also benefit from membership. Visit us at www.myscrs.org.
SOURCE The Society for Clinical Research Sites (SCRS)